CeriBell, Inc.

NASDAQ:CBLL

Medical - Devices

Healthcare
$25.63 +1.42%

+$0.25 today

Market cap
$995.34M
Beta
0.84
P/E (TTM)
-10.9
EPS (TTM)
-$1.60
52W Low $10.85High $24.33

Volume 0.41M

Average 0.29M

CBLL Net Income

Bottom-line profit after all expenses, interest, and taxes.

CeriBell, Inc.NASDAQ: CBLL

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$19.74M, compared with -$12.78M a year earlier. Trailing-twelve-month net income was -$60.37M.

Context

  • Net income amounted to 60.0% of revenue in FY2025, down 1.8 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$73.43M (-37.5%) for the fiscal year ending Dec 2026, a slowdown from the -32.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.74M-45.9% QoQ
Last fiscal yearDec 2025
-$53.41M-32.0% YoY
LTMMar 2026
-$60.37M-35.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.5%-33.0%+21.5 pp
1 year-32.0%-37.5%-5.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(53.41M) USD
Year-over-year change
-32.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CBLL compares with its peers on the latest reported figures

  • CBLL's LTM Mar 2026 net income of -$60.37M is the lowest of the 7 companies compared; the peer median is -$18.47M.
  • Its year-over-year change of -35.7% is the lowest of 7, against a peer median of +18.3%.
  • Net income amounts to 63.5% of revenue for CBLL, versus a peer median of 23.1%.
CBLL Competitors Peer median
Net Income for CBLL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LIVNLivaNova PLCLTM Sep 2026$196.08M +190.2%—13.0%
BWAYBrainsWay Ltd.LTM Mar 2026$8.82M +125.1%—15.7%
ECORelectroCore, Inc.LTM Mar 2026-$15.38M -25.7%—44.1%
NPCENeuroPace, Inc.LTM Mar 2026-$21.57M +13.1%—21.7%
STIMNeuronetics, Inc.LTM Mar 2026-$37.11M +23.5%—24.5%
CVRXCVRx, Inc.LTM Mar 2026-$52.66M -2.2%—89.1%
CBLLCeriBell, Inc.LTM Mar 2026-$60.37M -35.7%—63.5%
Peer median (excluding CBLL) -$18.47M+18.3%—23.1%

Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.92M45.23M65.44M89.06M
Cost of Revenue4.43M7.06M8.69M10.79M
Gross Profit21.49M38.16M56.75M78.27M
Gross Margin82.9%84.4%86.7%87.9%
Research & Development7.24M9M13.56M19.14M
Selling, General & Admin50.27M59.21M82.9M117.53M
Operating Expenses57.51M68.2M96.46M136.68M
Depreciation & Amortization497K847K1.14M1.34M
EBITDA(35.06M)(26.51M)(37.32M)(50.18M)
EBITDA Margin-135.3%-58.6%-57.0%-56.3%
Operating Income(36.02M)(30.04M)(39.71M)(58.4M)
Operating Margin-139.0%-66.4%-60.7%-65.6%
Interest Income0000
Interest Expense1.6M2.1M1.99M1.89M
Other Income / Expenses(1.14M)588K(746K)4.99M
Income Before Tax(37.16M)(29.45M)(40.46M)(53.41M)
Pre-Tax Margin-143.4%-65.1%-61.8%-60.0%
Income Tax Expense2K11K00
Net Income(37.16M)(29.46M)(40.46M)(53.41M)
Net Margin-143.4%-65.1%-61.8%-60.0%
EPS (Basic)(1.59)(1.26)(3.39)(1.46)
EPS (Diluted)(1.59)(1.26)(3.39)(1.46)
Weighted Avg Shares23.32M23.32M11.95M36.54M
Weighted Avg Shares (Diluted)23.32M23.32M11.95M36.54M

CeriBell, Inc.

NASDAQ:CBLL

Intrinsic Alpha fair value

Locked

Current Price

$25.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.